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ABSTRACT 
 
Background: Although serum level of alpha-fetoprotein (AFP) has long been used to 
complement imaging tests in the screening and diagnosis of hepatocellular carcinoma 
(HCC), whether it can be used as a predictive marker of long-term risk for developing 
HCC in patients with hepatitis B virus (HBV) has not been extensively evaluated and 
thus remains controversial. 
Methods: We retrospectively conducted a clinic-based longitudinal cohort study 
including 617 Korean American patients with HBV who had been followed for up to 22 
years (median follow-up time, 6.2 years) to evaluate the association between baseline 
serum AFP level and the long-term risk of HCC. 
Results: The median baseline AFP value of these patients was 3.8 ng/ml. Compared to 
patients with lower-than-median AFP value, those with higher-than-median baseline 
serum AFP had a significantly increased risk of developing HCC with an hazard ratio 
(HR) of 2.73 (95% confidence interval [CI] 1.25-5.99), independent of other major HCC 
risk factors. In addition, we calculated the cumulative incidence of HCC during different 
years of follow-up time by baseline serum AFP, and found that the cumulative incidence 
of HCC was significantly higher in HBV patients with high baseline serum AFP 
compared to those with low baseline serum AFP in each of the five follow-up time 
periods examined. 
Conclusions: Our results indicated that AFP was a strong independent prospective 
predictor of long-term HCC risk in high-risk HBV patients. More targeted prevention and 
early detection of HCC may be considered for these patients.
 4 
INTRODUCTION 
 
Hepatocellular carcinoma (HCC) is the fifth most common solid malignancy and 
the third leading cause of cancer mortality worldwide, with approximately 625,000 new 
cases and 600,000 deaths in each year (1-3). Hepatitis B virus (HBV) is the most 
significant hepatocarcinogen which is responsible for up to 80% of HCC worldwide. 
Currently there are over 400 million patients with chronic HBV infection globally which 
corresponds to over 5% of the world’s population; and it is estimated that about 20% of 
these infected individuals may eventually develop HCC (4, 5). The hepatocarcinogenesis 
from HBV infection to HCC development has been increasingly recognized as a 
multifactorial and multistep process. Observational studies have identified potential 
demographic factors, viral status, clinical variables, and genetic components in HBV 
patients that are associated with the risk of HCC (6-8). Although acclaimed instrumental, 
many of these factors remain controversial in their roles for predicting the long-term risk 
of developing HCC (6). Thus, validation of these significant risk factors for HCC would 
allow further stratification of HBV patients and selection of those with the highest risk of 
HCC to receive more intensive, targeted, and personalized prevention strategies. 
Alpha-fetoprotein (AFP) was first identified in 1956 as a serum glycoprotein 
generated by the yolk sac and the liver during fetal life (9). Generally, normal people 
have a low AFP level, which may be elevated under certain diseases. Serum AFP has 
long been used as a diagnostic marker for HCC, but with controversies (10). Although 
still widely used in the current clinics, the use of AFP in HCC diagnosis has been 
challenged in recent years due to the associated false positive and false negative findings 
(11). In addition, the role of AFP as a prospective predictive marker or a surveillance 
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indicator of HCC among HBV patients has not been extensively evaluated and thus 
remains controversial (12-15). For example, in a prospective study including 463 patients 
with liver cirrhosis, AFP was not significantly associated with HCC development within 
a mean follow-up time of 3.2 years (14). In comparison, Oka et al. reported a significant 
positive correlation between high baseline AFP value and increased incidence of HCC in 
a cohort of 260 Japanese patients within a 5-year follow-up period (12). Consistently, 
Colombo et al. reported that the risk of developing HCC in patients with persistently high 
levels of AFP was more than 10 times higher than those patients with persistently low 
AFP levels (15). The lack of consistency in findings from these studies are likely 
accounted for by various factors, such as study design, population size and 
characteristics, patient enrollment criteria, HCC etiology, and follow-up time. 
Nonetheless, given the broad application of AFP measurement in the current clinics on 
HCC screening, surveillance, diagnosis, and treatment, additional studies on the 
predictive role of baseline AFP in long-term risk of developing HCC are warranted to 
better assist clinicians to make informed decisions on HCC prevention and management. 
To further assess the relationship between baseline AFP and future HCC risk, we 
retrospectively conducted a clinic-based longitudinal cohort study based on a unique 
population of Korean American HBV patients in the Greater Philadelphia area who have 
been followed for up to 22 years. In this study, we evaluated the differences in HCC 
incidence between HBV patients with high and low level of baseline AFP values. To our 
knowledge, this is one of the largest clinic-based cohort studies with a long-time follow-
up. 
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MATERIALS AND METHODS 
Study population 
The subjects in this study were identified from an existing clinic-based patient 
cohort. The patients were consecutively enrolled from those who visited the Liver 
Disease Prevention Center at Thomas Jefferson University Hospital for treatment of 
chronic HBV or HCV infection and liver diseases, such as cirrhosis, fibrosis, and/or 
HCC. There were no restrictions on age, gender, ethnicity, and disease stage in patient 
enrollment. Enrollment was initiated from 1988 and is still ongoing. As of October 2010, 
the cohort included more than 2,600 patients, of which 90% were of Korean ancestry. 
The cohort included patients with different etiologies and conditions, including non-
cancer patients with mono-infection of HBV, hepatitis C virus (HCV), or without viral 
infection; and also included cancer patients with HBV-related HCC, HCV-related HCC, 
or HCC without viral infection. For each patient, viral infection status was clinically 
determined before enrollment. All demographic, clinical, and follow-up data for study 
subjects were obtained from medical chart review and consultation with the treating 
physicians. For the purpose of this study, we included all those patients who (a) were 
non-cancer patients who had only HBV infection at their first clinical visits, (b) had 
recorded AFP measurement within 12 months after their first clinical visit, (c) had been 
followed for a minimum of 12 months, and (d) was not diagnosed with HCC within 12 
months of their first clinical visit. Because the majority (>90%) of the patients who 
visited the Liver Disease Prevention Center were of Korean ancestry, we further 
restricted the study to Korean patients to eliminate the confounding effect from 
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population stratification. This study has been reviewed and approved by the Institutional 
Review Board (IRB) at the Thomas Jefferson University. 
Data collection 
Demographic and clinical data were abstracted from patient medical records to 
create a patient-level longitudinal database. Demographic variables collected included 
age, gender, ethnicity, smoking status, drinking status, self-reported family history of 
HBV infection, family history of cirrhosis, and family history of cancer. Clinical 
variables were collected for the first clinical visit with a recorded AFP value, including 
the presence of liver cirrhosis, serum AFP, alkaline phosphatase (ALP), Alanine 
Aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase 
(GGT), HBV DNA load, count of white blood cell (WBC) and platelets, prothrombin 
time, total protein, albumin, total bilirubin, direct bilirubin, ferritin, blood urine nitrogen 
(BUN), triglyceride, low-density lipid protein (LDL), and creatinine, etc. Missing data in 
these variables were noticed due to the retrospective nature of the chart review. The rate 
of missing data for these variables in the initial patients’ visits ranged from 0.91% (AST) 
to 39.9% (LDL). Liver cirrhosis and HCC status were determined by the combined use of 
clinical diagnosis and imaging studies (ultrasound, computed tomography, or magnetic 
resonance imaging) (16). Treatment data including antiviral nucleoside and nucleotide 
analogs and interferons were also obtained. More than 95% of these patients received 
nucleoside/nucleotide analog-based antiviral treatments. Less than 5% of patients 
received interferon-based or combined treatments. For those patients who developed 
HCC during follow-up, treatments usually included transarterial 
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embolization/chemoembolization (TACE) radiofrequency ablation (RFA), cryoablation, 
chemotherapy, and/or surgery.  
Statistical Analysis 
Statistical analyses were performed using the SAS software version 9.2 (SAS 
Institute, Cary, NC). Continuous variables were expressed as means with standard 
deviation (SD), and were compared using the student’s t test or ANOVA as appropriate. 
Categorical variables were compared using the chi-square test or Fisher’s exact test, 
where appropriate. The primary outcome of this study was the diagnosis of HCC. Time to 
the HCC diagnosis was defined as the time from the date of first visit to the date of HCC 
diagnosis, or the date of last follow-up if the patient was still alive without HCC 
diagnosis at the time of this analysis. Patients free of HCC at their death or at the last 
follow-up date were censored for the analysis. Incidence rates of HCC were calculated by 
dividing the number of incident HCC cases by the total number of person-years of 
follow-up. Cumulative incidence of HCC by follow-up year was derived using the 
Nelson-Aalen method (17). Kaplan-Meier analysis was used to compare the cumulative 
risk for developing HCC in patients with different levels of serum AFP. The log rank test 
was used to determine the statistical significance of associations. The baseline AFP value 
was treated as continuous predictor variable and grouped based on the median and tertile 
distribution in all patients included in the analyses. Cox proportional hazards model was 
performed to determine the association between the independent variables and the risk of 
developing HCC. The risk of HCC was estimated using hazard ratio (HR) and 95% 
confidence interval (CI) after adjustment for age, gender, smoking, drinking, cirrhosis, 
family history of HBV, family history of cirrhosis, and family history of cancer, where 
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appropriate. All statistical tests in this study were two-sided, and P<0.05 was considered 
statistically significant. 
 
RESULTS 
Population Characteristics 
From our database of patients enrolled from 1988 to 2010, we identified a total of 
617 cancer-free Korean HBV patients who met the criteria described in the study 
population in Materials and Method. Patients who developed HCC within 12 months of 
their first clinical visits were excluded from the analyses. The basic demographic 
characteristics of the 617 patients are listed in Table 1. The median (SD) age of all 
patients was 42.1 (11.1) years. The majority of patients were males (67.6%), never 
smokers (66.8%), and never drinkers (60.9%). Approximately 36.8% of the patients had 
cirrhosis at the time of enrollment. There were an equal number of patients with and 
without a family history of HBV infection (49.4% vs. 50.6%, respectively). The majority 
of patients did not have a family history of cirrhosis (81.2%) or family history of cancer 
(66.0%). The median level of baseline AFP (first measured within 12 months of first 
clinic visit) of these patients was 3.8 ng/ml (Table 1).   
Incidence rate and risk factors associated with the development of HCC 
There were a total of 3,785 person-years of follow-up in the 617 study subjects, 
with the average (SD) follow-up time period of 6.2 (4.7) years (range: 1.0-22.2 years). 
During follow-up, a total of 61 HBV patients developed HCC after 12 months. We 
analyzed the association of major demographic variables and baseline serum AFP value 
with the risk of developing HCC using multivariate Cox proportional hazard model 
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(Table 2). We found that male patients, ever smokers, and ever drinkers exhibited an 
increased but non-significant risk of HCC development with an HR of 1.90 (95% CI 
0.84-4.30), 1.65 (0.81-3.34), and 1.10 (0.56-2.16), respectively. Compared to patients 
≤39 years old, patients who were 40-49 years old, 50-59 years old, and over 60 years old 
showed an increased risk for developing HCC, with an HR (95%CI) of 1.45 (0.71-2.96), 
6.28 (3.12-12.63), and 2.11 (0.85-11.40), respectively. As expected, patients with 
cirrhosis had a statistically significantly increased risk of developing HCC (HR=8.02, 
95% CI 3.38-19.05). Furthermore, patients who reported a family history of cirrhosis also 
had a significantly increased risk of HCC with an HR (95% CI) of 3.20 (1.09-9.43). 
However, no significant associations were observed between HCC risk and self-reported 
family history of HBV infection (HR 0.94, 95% CI 0.52-1.69) and family history of 
cancer (HR 1.13, 95% CI 0.65-1.99). There were 300 patients with a baseline AFP level 
that was lower than the median value. In this group, 15 (5.0%) patients developed HCC 
in an average of 7.9 years. In comparison, 46 of 317 (14.5%) patients with an AFP level 
higher than the median value developed HCC in an average of 4.6 years (chi square test < 
0.0001, data not shown). Multivariate Cox proportional hazard analysis indicated that 
compared to patients with a lower-than-median serum AFP, those with a higher-than-
median serum AFP value had a 2.73-fold (95% CI 1.25-5.99) increase in the risk for 
developing HCC (Table 2). The incidence rates of HCC per 100,000 person-years by 
baseline serum AFP level increased from 801 per 100,000 person-years for the low AFP 
group to 2405 per 100,000 person-years for the high AFP group (Table 2). Moreover, a 
significant difference in AFP levels was identified between HBV patients who developed 
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and who did not develop HCC during follow up (P value for t test, 0.008, data not 
shown).  
Cumulative incidence of HCC by serum AFP level during complete follow-up 
The cumulative incidence of HCC during the complete follow-up period (1988-
2010) is shown in Figure 1. An increasing trend of cumulative HCC incidence over the 
follow-up period was noted, with significantly higher cumulative incidence observed in 
HBV patients with higher-than-median baseline serum AFP level compared to those 
HBV patients with lower-than-median AFP levels (log-rank P<0.0001, Figure 1A). Very 
similar results were obtained when the tertile distribution of baseline serum AFP value 
was used to separate patients, indicating that the association between elevated baseline 
AFP and increased risk of HCC was dose-dependent (Figure 1B). Because the population 
in this analysis included HBV patients whose AFP level was measured within 12 months 
of the first clinical visit and who had a minimum of 12 months follow-up period, there 
was a possibility that some patients with high AFP value actually already had cancer but 
were not diagnosed at the time of AFP measurement. The inclusion of these patients 
might confound our results, because the elevated AFP value in these patients was more 
like a marker of cancer detection than a predictive marker of long-term cancer risk. To 
address this potential cofounder, we calculated the average time from first clinic visit to 
AFP measurement as well as the average time from first clinic visit to HCC diagnosis. 
We found that for 419 of the 617, the AFP measurement was conducted at the same date 
of their first clinic visit. The average time of AFP measurement from the first clinic visit 
was 1.3 months whereas the average time of HCC diagnosis from the first clinic visit was 
5.1 years. Moreover, we further restricted the patient cohort to include only those patients 
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who had the baseline serum AFP measurement done within 6 months of first clinical visit 
as well as had been followed up for a minimum of 36 months and excluded those patients 
who developed HCC within 12 months. This approach yielded a total of 363 non-cancer 
HBV patients, among which 37 patients developed HCC after 36 months of follow-up 
(data not shown). We then evaluated the cumulative incidence of HCC within this patient 
cohort. Very similar results to that of the previous cohort were attained (Figure 2). That 
is, the cumulative incidence of HCC was again significantly higher in those patients with 
a higher-than-median AFP value, compared to those with a lower-than-median AFP value 
(Figure 2A). Furthermore, we found that this effect was also in a significant dose-
response manner when the tertile, instead of median, distribution of baseline AFP was 
used to group subjects (Figure 2B).  
Cumulative incidence of HCC by serum AFP level at different years of follow-up 
Finally, we conducted analyses to calculate the cumulative incidence of HCC 
during different years of follow-up time by serum AFP level using the Nelson-Aalen 
method (Table 3). We found that the cumulative incidence of HCC was significantly 
higher in patients with higher baseline serum AFP than those with lower AFP value, in 
each of the follow-up time periods examined. In patients with lower-than-median 
baseline AFP value, the cumulative incidence of HCC was 2.4, 3.9, 5.2, 10.0, and 17.9 at 
the end of 3, 6, 9, 12, and more than 18 years of follow-up, respectively. In comparison, 
HCC incidence was 6.6, 10.9, 15.5, 27.8, and 40.8, respectively, in patients with higher-
than-median baseline AFP values (Table 3, upper panel). Very similar results were 
observed when the analysis was conducted within those 363 patients whose baseline AFP 
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was measured within 6 months of first clinical visit and had been followed for more than 
36 months (Table 3, lower panel).   
 
DISCUSSION 
Despite the wide application of serum AFP level in complementing other 
imaging-based approaches in HCC diagnosis, there is uncertainty about whether baseline 
level of AFP can predict the long-term risk of developing HCC in HBV patients (10, 12, 
14). Through a retrospective analysis of a clinic-based well-characterized and 
homogeneous HBV patient cohort that have been followed for up to 22 years, we found 
that baseline serum AFP level was a strong indicator of the development of HCC, 
independent of other demographic risk factors including age, gender, smoking, drinking, 
cirrhosis, family history of HBV, family history of cirrhosis, and family history of cancer. 
With a median follow-up time of 6.2 years, the HBV patients who had high baseline 
serum AFP value exhibited a 2.73-fold increase in HCC risk compared to patients with 
low AFP value. In addition, the cumulative incidence of HCC at the end of 18 years 
follow-up was significantly higher in patients with high baseline AFP (40.8%) than those 
with low baseline AFP (17.9%).  
Compared to prospectively designed population-based or clinic-based studies, a 
potential caveat for retrospective analysis of clinic-based cohort was patient selection 
bias (18). However, when we compared the major demographic characteristics between 
the 617 HBV patients included in this study to the rest of HBV patients in our cohort that 
were not included in this study due to lack of measurement of baseline AFP value and/or 
short follow-up time, we did not identify any significant differences (P value ranged from 
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0.21 to 0.89, data not shown), indicating the chance was low for bias in patient selection 
in our study. In addition, the risk association of other demographic variables calculated 
by multivariate analyses was consistent with the findings from previous reports in other 
Asian populations. For example, compared to patients less than 40 years old, patients 
who were between 40 to 49 and 50-59 had a 1.45-fold and 6.28-fold increase in HCC 
risk, respectively, consistent with the previous reports that older patients were more likely 
to develop HCC in HBV patients (17, 19). However, the risk was 2.11 (95% CI 0.85-
11.40) in patients with an age of more than 60 years in our study, which was probably 
due to the small number (N=3) of HCC patients in this age group that led to an unstable 
estimate. Moreover, we found that HBV patients in our population who had liver 
cirrhosis had a more than 8-fold increase in the risk of developing HCC, which was also 
consistent with many previous reports on the significant positive correlation between 
cirrhosis and HCC in previous studies. For example, Chen et al. reported that cirrhosis 
was associated with a 21.8-fold increased HCC risk in a population-based HBV patient 
cohort (19). The difference in the magnitude of increase in HCC risk between our study 
(8.02) and the study from Chen et al. (21.8) could be due to the differences in patient 
ethnicity, sample size, and clinic and population-based studies. Further, consistently we 
found in our study that the family history of liver cirrhosis was also an independent 
predictor of HCC development (Table 2). Other previously reported significant risk 
factors such as male gender, ever smokers, and ever drinkers were also found in our study 
to be associated with increased HCC risk. However, these associations did not reach 
statistical significance. These discrepancies could be due to the nature of clinic-based 
study in which most patients have higher disease severity than those patients in the 
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general HBV population. The severity of HBV infection and relevant induced condition 
could overshadow the effects of other demographic risk factors on HCC development. In 
consistency with this notion, the lack of significant association between several major 
demographic and clinical risk factors and the risk of developing HCC was also noted in 
other independent clinic-based studies (13, 14, 20, 21). 
The major strength of our study is the unique and highly homogenous HBV 
patient population that has been completely collected in a single institute. In addition, in 
comparison to many previous studies that did not differentiate HCC cases with different 
etiologies, our study was focused on HCC risk in patients infected with HBV only. All 
subjects were of Korean ethnicity to eliminate the confounding effects of population 
stratification. In addition, the majority of the patients in our study were infected with 
HBV at birth or childhood, making our population an ideal resource to study the long-
term outcome of HBV infection at the population level. Our study also has limitations. 
First, due to the nature of clinic-based research, the findings from this study might not be 
generalized to the general population with HBV infection. Instead, the conclusion of our 
study might be more applicable to high-risk HBV patients who visit clinics and seek 
medical advice and/or treatment. Moreover, different AFP levels have been reported in 
different ethnic groups. For example, it has been reported that in the general male 
population, AFP levels were higher in Africans than in Asians (22). O’Brien et al. found 
that normal Asian and African American women exhibited a higher AFP level than 
Hispanic and White American women (23). Consistently, Lok et al. reported a higher 
AFP level in African Americans than Caucasians (24). Since our study is restricted to 
Korean HBV patients, whether the finding can be generalized to other ethnic groups 
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remains a task of further evaluation. Second, all the data used in this study were obtained 
from medical chart review instead of in-person interview, although we had strict criteria 
for quality control of chart review as well as frequent validation with treating physicians. 
Third, we also had missing values for some major clinical variables such as the status of 
HBe Ag and anti-HBe, viral DNA load, levels of ALT and AST, etc. These variables 
were not included in our multivariate adjustment and thus might confound our results. 
However, when we used the first available measurement of these variables within 12 
months of first patient clinical visit, the rate of missing data was significantly reduced yet 
the inclusion of these variables in the adjustment of multivariate analyses did not 
significantly changed our results (high vs. low AFP, HR=2.37, 95% CI 1.19-3.87, data 
not shown). Fourth, although we observed an increased HCC risk associated with 
drinking status, a commonly recognized HCC risk factor, the association did not reach 
statistical significance (Table 2). This might be due to the nature of our clinic-based 
cohort in which the severity of HBV patients has overshadowed the causal relationship of 
drinking. It is also possible that the current categorization of never and ever drinkers is 
not sufficient to accurately reflect the intensity of drinking. This issue may not be able to 
be addressed using our current patient population and thus, warrants further 
investigations, especially in a prospective setting. Finally, the cut-off of AFP used in this 
study was determined using the median baseline value among all patients (3.8 ng/ml). 
Thus, it remains to be determined whether this cut-off is applicable to different patients in 
other clinical settings. A cut-off value ranged from 5 to 20 ng/ml has been reported in 
other clinic-based studies as having good discriminative capability (12, 14, 24, 25). Using 
a cut-off of 20 ng/ml in our study resulted in a small number of patients whose AFP was 
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higher than the cut-off, which in turn led to an unstable estimate. However, a cut-off of 
both 5 ng/ml and 10 ng/ml significantly differentiated HBV patients with different risks 
of developing HCC in our study (log rank P<0.001 in both analyses). Nonetheless, future 
larger studies are still warranted to further determine the optimum clinically applicable 
AFP value in clinic-based HBV patients. Taken together, these caveats limit the clinical 
applicability of the findings in our study. Prospective studies in independent populations 
are warranted to further validate our findings.  
In summary, we retrospectively conducted a clinic-based longitudinal cohort 
study to determine the predictive role of baseline AFP value in the prediction of long-
term risk of developing HCC in HBV patients. Our conclusion was that elevated serum 
AFP was significantly associated with increased risk of HCC in HBV patients who seek 
medical advice/treatment. The effect of high AFP on increased risk of HCC might last for 
many years after the AFP measurement. Although it still remains a topic of further debate 
as to whether AFP should be an integral component for HCC surveillance in the general 
HBV patient population, our study indicated that high levels of serum AFP were 
associated with higher risk of developing HCC in non-cancer HBV patients. Thus, more 
targeted prevention and early detection of HCC may be considered for these patients.
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FIGURE LEGENDS 
Fig. 1. Cumulative incidence of HCC by (A) median and (B) tertile distribution of 
baseline AFP level, conducted within patients with baseline AFP measured within 12 
months of first clinical visit and a minimum of 12 months’ follow-up. 
 
Fig. 2. Cumulative incidence of HCC by (A) median and (B) tertile distribution of 
baseline AFP level, conducted within patients with baseline AFP measured within 6 
months of first clinical visit and a minimum of 36 months’ of follow-up. 
 19 
REFERENCES 
 
1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: 
Globocan 2000. Int J Cancer 2001;94(2):153-6. 
2. Parkin DM. The global health burden of infection-associated cancers in the year 
2002. Int J Cancer 2006;118(12):3030-44. 
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and 
molecular carcinogenesis. Gastroenterology 2007;132(7):2557-76. 
4. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. 
Cancer 1988;61(10):1942-56. 
5. Blum HE, Moradpour D. Viral pathogenesis of hepatocellular carcinoma. J 
Gastroenterol Hepatol 2002;17 Suppl 3:S413-20. 
6. Kao JH, Chen PJ, Chen DS. Recent advances in the research of hepatitis B virus-
related hepatocellular carcinoma: epidemiologic and molecular biological aspects. Adv 
Cancer Res;108:21-72. 
7. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to 
environment. Nat Rev Cancer 2006;6(9):674-87. 
8. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular 
carcinoma. Hepatology 2008;48(6):2047-63. 
9. Bergstrand CG, Czar B. Demonstration of a new protein fraction in serum from 
the human fetus. Scand J Clin Lab Invest 1956;8(2):174. 
10. Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001;34(4):603-5. 
11. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 
2005;42(5):1208-36. 
12. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of 
alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular 
carcinoma. Hepatology 1994;19(1):61-6. 
13. Chen TH, Chen CJ, Yen MF, Lu SN, Sun CA, Huang GT, et al. Ultrasound 
screening and risk factors for death from hepatocellular carcinoma in a high risk group in 
Taiwan. Int J Cancer 2002;98(2):257-61. 
14. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, 
et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with 
liver cirrhosis. Hepatology 2003;37(3):520-7. 
15. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, 
Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J 
Med 1991;325(10):675-80. 
16. Digumarthy SR SD, Saini S. MRI in detection of hepatocellular carcinoma 
(HCC). Cancer Imaging 2005;5(1):20-24. 
17. Chen CJ YH, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH; REVEAL-
HBV Study Group. Risk of Hepatocellular Carcinoma Across a Biological Gradient of 
Serum Hepatitis B Virus DNA Level. JAMA. 2006;295(1):65-73. 
18. Frazee RC, Roberts JW, Symmonds RE, Snyder SK, Hendricks JC, Smith RW, et 
al. A prospective randomized trial comparing open versus laparoscopic appendectomy. 
Ann Surg 1994;219(6):725-8; discussion 728-31. 
19. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in 
chronic hepatitis B. Hepatology 2009;49(5 Suppl):S72-84. 
 20 
20. Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, et al. Genotype C 
hepatitis B virus infection is associated with an increased risk of hepatocellular 
carcinoma. Gut 2004;53(10):1494-8. 
21. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, et al. Independent 
risk factors and predictive score for the development of hepatocellular carcinoma in 
chronic hepatitis B. J Hepatol 2009;50(1):80-8. 
22. Sizaret P, Tuyns A, Martel N, Jouvenceaux A, Levin A, Ong YW, et al. Alpha-
Fetoprotein levels in normal males from seven ethnic groups with different hepatocellular 
carcinoma risks. Ann N Y Acad Sci 1975;259:136-55. 
23. O'Brien JE, Dvorin E, Drugan A, Johnson MP, Yaron Y, Evans MI. Race-
ethnicity-specific variation in multiple-marker biochemical screening: alpha-fetoprotein, 
hCG, and estriol. Obstet Gynecol 1997;89(3):355-8. 
24. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. 
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early 
detection of hepatocellular carcinoma. Gastroenterology;138(2):493-502. 
25. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni 
P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients 
with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 
2001;34(4):570-5. 
 
 21 
Table 1. Baseline characteristics of the HBV patients included in this study  
 
 
 
Variables Number (%) of patients (N=617) 
Age (Mean  SD *) 42.2  11.1 
Gender  
Male 417 (67.6) 
Female 200 (32.4) 
Smoking status  
Never  412 (66.8) 
Ever 205 (33.2) 
Drinking status  
Never 376 (60.9) 
Ever 241 (39.1) 
Cirrhosis  
No 390 (63.2) 
Yes 227 (36.8) 
Family history of HBV infection  
No 305 (49.4) 
Yes 312 (50.6) 
Family history of cirrhosis  
No 501 (81.2) 
Yes 116 (18.8) 
Family history of cancer  
No 407 (66.0) 
Yes 210 (34.6) 
AFP  
 median 300 (48.6) 
> median 317 (51.4) 
* SD, standard deviation   
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Table 2. The associations of demographic variables and serum AFP value with the 
risk of developing HCC in HBV patients. 
 
 
Variables 
Number 
(%) of 
patients 
(N=617) 
Person-
years of 
follow-up 
Number 
(%) of 
HCC 
cases 
(N=61) 
Incidence 
rate per 
100,000 
person-years 
HR (95% CI) * P value 
Age (Year) 
   ≤39 233(40.88) 1651 8 485 Reference 
   40-49 194(34.04) 1179 17 1442 1.45 (0.71-2.96) 0.30 
   50-59 108(18.95) 531 26 4896 6.28 (3.12-12.63) <0.0001 
   ≥60 35(6.14) 148 3 2027 2.11 (0.85-11.40) 0.09 
Sex 
   Female 200(32.41) 1160 9 776 Reference 
   Male 417(67.59) 2625 52 1981 1.90 (0.84-4.30) 0.12 
Smoking status 
Never 412(66.77) 2544 29 1140 Reference 
   Ever 205(33.23) 1241 32 2579 1.65 (0.81-3.34) 0.17 
Drinking status 
   No 376(60.94) 2369 30 1266 Reference 
   Yes 241(39.06) 1416 31 2189 1.10 (0.56-2.16) 0.78 
Cirrhosis 
   No 390(63.21) 2315 7 302 Reference 
   Yes 227(36.79) 1470 54 3673 8.02 (3.38-19.05) <0.0001 
Family history of HBV 
   No 305(49.31) 1894 31 1637 Reference 
   Yes 312(50.57) 1891 30 1586 0.94 (0.52-1.69) 0.83 
Family history of cirrhosis 
   No 501(81.20) 3106 45 1449 Reference 
   Yes 116(18.80) 679 16 2356 3.20 (1.08-9.43) 0.04 
Family history of cancer 
   No 407(65.96) 2547 37 1453 Reference 
   Yes 210(34.04) 1238 24 1939 1.13 (0.65-1.99) 0.67 
AFP 
≤median 300(48.62) 1872 15 801 Reference 
>median 317(51.38) 1913 46 2405 2.73 (1.25-5.99) 0.01 
* Adjusted for age, sex, smoking status, drinking status, cirrhosis, family history of HBV, family 
history of cirrhosis, family history of cancer, and AFP, where appropriate. 
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Table 3. Cumulative incidence of HCC by baseline serum AFP level and different 
years of follow-up in patients. 
 
Years of follow-up 
 
Baseline serum AFP(≤ median) Baseline serum AFP(≥median) 
Cumulative incidence Cumulative incidence 
In patients with more than 12 month’s follow-up* 
3 2.4 6.6 
6 3.9 10.9 
9 5.2 15.5 
12 10.0 27.8 
≥18 17.9 40.8 
In patients with more than 36 month’s follow-up** 
6 1.7 5.1 
9 3.0 10.3 
12 8.0 24.1 
≥18 16.1 37.8 
* Within patients who had an AFP value within 12 months of first clinical visit and who had been 
follow-up for at least 12 months. 
** Within patients who had an AFP value within 6 months of first clinical visit and who had been 
follow-up for at least 36 months 
 
